# DP

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

NI et al.

Appl. No. 09/448,868

Filed: November 24, 1999

For:

**Death Domain Containing** 

**Receptor-4 Antibodies** 

Art Unit:

1646

Examiner:

To be assigned

Atty. Docket: 1488.1300004/EKS/EJH

# Second Supplemental Information Disclosure Statement

Commissioner for Patents Washington, D.C. 20231

Sir:

Applicants wish to bring to the attention of the Examiner that SEQ ID NO: 1 and the corresponding clones of the captioned application may be related to SEQ ID NO: 4784 in copending U.S. Application No. 08/799,180, filed February 12, 1997, SEQ ID NO: 11108 in U.S. Application No. 08/798,074, filed February 12, 1997 and SEQ ID NO: 625 in U.S. Application No.08/975,985, filed November 21, 1997. In addition, Applicants wish to bring to the attention of the Examiner co-pending U.S. Patent Application No. 09/565,918, filed May 5, 2000. The identification of these U.S. Patent Applications are not to be construed as a waiver of secrecy as to these applications now or upon issuance of the captioned application as a patent.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

It is further understood that the Examiner will consider information that had been cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

This Second Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this pleading is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Elizabeth J. Haanes, Ph.D.

Agent for Applicants Registration No. 42,613

Date: august 15, 2000

1100 New York Avenue, N.W. Suite 600
Washington, D.C. 20005-3934

Washington, D.C. 20005-3934 (202) 371-2600

P:\USERS\MDESAI\1488\1300004\idspldg\_2\_1488 1300004 SKGF Rev. 4/27/00 mac





RECEIVED

# TECH CENTER 1600/2900

## STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW


MASHINGTON, D.C. 20005-3934

www.skgf.com

PHONE: (202) 371-2600

FACSIMILE: (202) 371-2540

ROBERT GREENE STERNE EDWARD J. KESSLER JORGE A. GOLDSTEIN SAMUEL L. FOX DAVID K.S. CORNWELL ROBERT W. ESMOND TRACY-GENE G. DURKIN MICHELE A. CIMBALA MICHAEL B. RAY ROBERT E. SOKOHL ERIC K. STEFFE MICHAEL O. LEE



HEIDI L. KRAUS
JEFFREY R. KURIN
RAYMOND MILLIEN
PATRICK D. O'BRIEN
LAWRENCE B. BUGAISKY
CRYSTAL D. SAYLES\*
EDWARD W. YEE
ALBERT L. FERRO\*
DONALD R. BANOWIT
PETER A. JACKMAN
MOLLY A. MCCALL
TERESA U. MEDLER

JEFFREY S. WEAVER
KRISTIN K. VIDOVICH
KENDRICK P. PATTERSON
DONALD J. FEATHERSTONE
GRANT E. REED
VINCENT L. CAPUANO
JOHN A. HARROUN\*
MATTHEW M. CATLETT\*
NATHAN K. KELLEY\*
ALBERT J. FASULO II \*
W. BRIAN EDGE\*

KAREN R. MARKOWICZ\*\*
SUZANNE E. ZISKA\*\*
BRIAN J. DEL BUONO\*\*
ANDREA J. KAMAGE\*\*
NANCY J. LEITH\*\*
TARJA H. NAUKKARINEN\*\*

\*BAR OTHER THAN D.C.
\*\*REGISTERED PATENT AGENTS

August 14, 2000

WRITER'S DIRECT NUMBER: (202) 218-7834
INTERNET ADDRESS:
BHAANES@SKGF.COM

Attn: Group Art Unit 1646

Commissioner for Patents Washington, D.C. 20231

Re:

U.S. Utility Patent Application

Appl. No. 09/448,868; Filed: November 24, 1999

For: Death Domain Containing Receptor -4 Antibodies

Inventors:

Ni et al.

Our Ref:

1488.1300004/EKS/EJH

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Second Supplemental Information Disclosure Statement (in duplicate); and
- 2. Return receipt postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.